Biogen/Elan Tysabri Combination Use Higher Than Expected Since Launch
Executive Summary
Demand for Biogen Idec/Elan's Tysabri for combination use with other multiple sclerosis therapies has been greater than expected in the product's first two months on the market
You may also be interested in...
Tysabri Return To Market With Expanded Indication Backed By Committee
Biogen Idec's Tysabri could return to market as early as April with an expanded indication following review by FDA's Peripheral & Central Nervous System Drugs Advisory Committee on March 7-8
Tysabri Return To Market With Expanded Indication Backed By Committee
Biogen Idec's Tysabri could return to market as early as April with an expanded indication following review by FDA's Peripheral & Central Nervous System Drugs Advisory Committee on March 7-8
Tysabri Withdrawn Pending Analysis Of Safety Signal In Long-Term Trial
Biogen Idec and Elan are convening a panel of experts on progressive multifocal leukoencephalopathy as the first step towards reintroducing the multiple sclerosis therapy Tysabri (natalizumab)
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: